Related Experiment Video
Updated: Feb 17, 2026

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
Motivations for Cannabis Use During Pregnancy: An Analysis of 2017-2021 Pregnancy Assessment Monitoring System Data
Kara R Skelton1, Stacey E Iobst2, Sara E Benjamin-Neelon1
1Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Background:
Prenatal cannabis use is becoming increasingly prevalent throughout the United States. Yet little is known about how motivations for cannabis use vary across maternal sociodemographic characteristics or how motivations are related to frequency of use. We aimed to address these evidence gaps via a comprehensive descriptive analysis of existing surveillance system data.
Methods:
Using data from the 2017-2021 Pregnancy Risk Assessment Monitoring System Marijuana Supplement, we estimated weighted prevalence estimates of self-reported motivations for cannabis use during pregnancy. We examined variations in motivations across sociodemographic characteristics and frequency of use. We also examined write-in responses for motivations for cannabis use.
Findings:
In our sample representing approximately 802,954 live births from 10 U.S. states, the most common motivations for prenatal cannabis use were for mental health reasons (82.81%; 95% confidence interval [CI]: 77.52, 87.06), to relieve gastrointestinal symptoms (77.10%; 95% CI: 70.51, 82.59), to relieve pain during pregnancy (48.67%; 95% CI: 41.84, 55.56), for fun or relaxation (40.18%; 95% CI: 33.69, 47.04), and to relieve symptoms of a chronic condition (26.31%; 95% CI: 20.55, 33.01). Most women (84.32%) reported two or more reasons for use, which was associated with daily or near-daily use. Qualitative analysis of write-in responses identified alleviation of pregnancy-related symptoms (e.g., nausea/vomiting, appetite, sleeplessness) as the most common motivation for use (54.90%).
Conclusions:
Given a growing body of evidence about adverse health outcomes associated with prenatal cannabis use, findings underscore the importance of patient-provider communication and messaging about safe alternatives to cannabis use during pregnancy.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Statistical Methods for Analyzing Epidemiological Data

